Geode Capital Management LLC Boosts Stake in Verve Therapeutics, Inc. (NASDAQ:VERV)

Geode Capital Management LLC boosted its holdings in Verve Therapeutics, Inc. (NASDAQ:VERV) by 1.6% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,625,780 shares of the company’s stock after acquiring an additional 25,093 shares during the quarter. Geode Capital Management LLC owned about 1.92% of Verve Therapeutics worth $9,172,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. GAMMA Investing LLC increased its holdings in shares of Verve Therapeutics by 189.7% in the 4th quarter. GAMMA Investing LLC now owns 6,054 shares of the company’s stock valued at $34,000 after purchasing an additional 3,964 shares in the last quarter. IFP Advisors Inc grew its position in Verve Therapeutics by 823,700.0% during the fourth quarter. IFP Advisors Inc now owns 8,238 shares of the company’s stock worth $47,000 after buying an additional 8,237 shares during the period. Impact Partnership Wealth LLC purchased a new position in Verve Therapeutics in the fourth quarter valued at about $70,000. China Universal Asset Management Co. Ltd. increased its holdings in Verve Therapeutics by 10.3% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 17,952 shares of the company’s stock valued at $101,000 after buying an additional 1,676 shares in the last quarter. Finally, KLP Kapitalforvaltning AS acquired a new stake in shares of Verve Therapeutics during the 4th quarter valued at approximately $101,000. Institutional investors and hedge funds own 97.11% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on VERV shares. Guggenheim upped their price target on Verve Therapeutics from $18.00 to $24.00 and gave the stock a “buy” rating in a report on Tuesday, April 15th. HC Wainwright raised their price target on Verve Therapeutics from $15.00 to $25.00 and gave the company a “buy” rating in a research report on Monday, April 14th. Canaccord Genuity Group boosted their price objective on shares of Verve Therapeutics from $32.00 to $39.00 and gave the stock a “buy” rating in a research report on Tuesday, April 15th. Cantor Fitzgerald upgraded shares of Verve Therapeutics from a “neutral” rating to an “overweight” rating in a report on Tuesday, April 15th. Finally, Royal Bank of Canada cut their target price on shares of Verve Therapeutics from $17.00 to $15.00 and set an “outperform” rating for the company in a research report on Tuesday, March 4th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $25.75.

Verve Therapeutics Stock Up 4.2 %

Shares of NASDAQ:VERV opened at $5.47 on Thursday. The company has a market capitalization of $485.71 million, a P/E ratio of -2.22 and a beta of 1.86. Verve Therapeutics, Inc. has a 52-week low of $2.86 and a 52-week high of $9.31. The stock’s fifty day simple moving average is $5.45 and its 200-day simple moving average is $5.92.

Verve Therapeutics (NASDAQ:VERV) last announced its earnings results on Thursday, February 27th. The company reported ($0.58) earnings per share for the quarter, beating the consensus estimate of ($0.72) by $0.14. Verve Therapeutics had a negative net margin of 807.65% and a negative return on equity of 35.23%. The firm had revenue of $13.08 million during the quarter, compared to the consensus estimate of $3.94 million. On average, sell-side analysts anticipate that Verve Therapeutics, Inc. will post -2.49 earnings per share for the current year.

Verve Therapeutics Company Profile

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.